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The characterization of pathogen-speciﬁc antigenic proteins at the
protein species level is crucial in the development and molecular
optimization of novel immunodiagnostics, vaccines or immunother-
apeutics for infectious diseases. The major requirements to achieve
this molecular level are to obtain 100% sequence coverage and
identify all post-translational modiﬁcations of each antigenic protein
species. In this article, we show nearly complete sequence informa-
tion for ﬁve discrete antigenic species of Candida albicans Tdh3
(glyceraldehyde-3-phosphate dehydrogenase), which have been
reported to be differentially recognized both among candidemia
patients and between candidemia and control patients. A compre-
hensive description of the top-down immunoproteomic strategy used
for seroproﬁling at the C. albicans protein species level in candidemia
as well as for the chemical characterization of this immunogenic
protein (based on high-resolution 2-DE, Western blotting, peptide
mass ﬁngerprinting, tandem mass spectrometry and de novo peptide
sequencing) is also provided. The top-down characterization data on
the speciation of the C. albicans immunome in candidemia presented
here are related to our research article entitled “Seroproﬁling at the
Candida albicans protein species level unveils an accurate molecular
discriminator for candidemia” (Pitarch et al., J. Proteomics, 2015,
http://dx.doi.org/10.1016/j.jprot.2015.10.022).
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.jprot.2015.10.022
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 The top-down immunoproteomic strategy described comprehensively in this data article, and used
in our research article [1], provides a coherent pipeline for the characterization of further
pathogen-speciﬁc antigens at the protein species level.
 The nearly complete sequence information included here for ﬁve discrete antigenic species of
C. albicans Tdh3 (glyceraldehyde-3-phosphate dehydrogenase) offers an important benchmark for
future studies directed at achieving their complete description [i.e. 100% sequence coverage and
the identiﬁcation of their post-translational modiﬁcations (PTMs)].
 Further research works concerning the analysis of the speciation of the immunome of C. albicans or
other pathogens during infection can take advantage of the top-down characterization data
presented in this article.1. Data
This dataset is part of our research article aimed toward proﬁling of the serologic response to the
C. albicans intracellular proteome at the protein species level in candidemia and control patients by
using immunoproteomics (serological proteome analysis) [1]. In contrast to other genomic, tran-
scriptomic, or bottom-up proteomic strategies based on serology, this top-down immunoproteomic
approach offers a powerful way for delineating the antibody responses to the smallest, chemically
deﬁned, and functional units of the immunome (or immunoproteome) of a pathogen (i.e. to the
different protein species of each of its antigens) during the infectious process. Here, we provide
detailed description of the experimental procedures employed for this seroproﬁling approach as well
as for the chemical characterization of a C. albicans immunogenic protein, i.e. glyceraldehyde-3-
phosphate dehydrogenase (Tdh3). Its ﬁve discrete protein species have shown differing antigenicities
both among candidemia patients and between candidemia and control patients [1]. Data on peptide
mass ﬁngerprints from these distinct C. albicans Tdh3 species are depicted in Supplementary Fig. S1.
These comprise masses detected, peptide assignments, matched peptides, sequence coverage and
annotated mass spectra for each of these ﬁve discrete antigenic protein species of C. albicans Tdh3,
which display different experimental pI -values.
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2.1. Serological proteome analysis (SERPA)
2.1.1. Preparation of C. albicans protoplast lysates
Protoplast lysates of a clinical C. albicans isolate (strain SC5314) were exploited as a source of
intracellular immunogenic proteins and prepared basically as reported [2,3]. In brief, yeast cells were
grown at 28 °C in YPD medium (1% Difco yeast extract, 2% peptone, and 2% D-glucose) up to an optical
density of 4 at 600 nm. After washing, cells were incubated at 28 °C in a pretreatment solution
(10 mM Tris–HCl, pH 9.0, 5 mM EDTA, and 1% 2-mercaptoethanol) for 30 min, and then in a 1 M
sorbitol solution containing 30 μg/mL glusulase (Du Pont, Boston, MA) until obtaining over 90%
protoplasts. After three gentle washes with 1 M sorbitol, protoplast cells were resuspended in 200 mL
cold lysis buffer (50 mM Tris–HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.5 mM PMSF, and
5 μg/mL each of pepstatin, leupeptin, and antipain (Sigma, St. Louis, MO)) and lysed by vortexing. The
clariﬁed supernatant was stored at 80 °C. Protein concentration was measured with the Bradford
assay (Bio-Rad, Hercules, CA), using bovine serum albumin (Sigma) as a calibrator.
2.1.2. Two-dimensional polyacrylamide gel electrophoresis (2-DE)
Proteins from C. albicans protoplast lysates were separated by 2-DE as described [2,4]. Brieﬂy,
protein samples (350 μg) were incubated in a rehydration buffer [7 M urea, 2 M thiourea, 2% CHAPS,
65 mM DTE, 0.5% immobilized pH gradient (IPG) buffer pH 3–10 (GE Healthcare, Buckinghamshire,
UK), and 0.002% bromophenol blue] for 30 min. Proteins were absorbed onto IPG strips (pH 3–10
nonlinear; 18 cm; GE Healthcare) at 15 °C for 16 h, and then focused on an IEF system (IPGphor; GE
Healthcare) at 15 °C using a stepwise increasing voltage (500 V for 1 h, 500–2000 V for 1 h, and
8000 V for 9.5 h). After that, the IPG strips were ﬁrst reduced (2% DTT) and then alkylated (2.5%
iodoacetamide) in an equilibration buffer (6 M urea, 50 mM Tris–HCl, pH 6.8, 30% glycerol, 2% SDS) for
12 and 15 min, respectively. Isoelectric focused proteins were subsequently resolved by SDS-PAGE
using homogeneous gels (10% T, 1.6% C) and an electrophoresis chamber (Protean II xi cell; Bio-Rad).
The 2-DE-separated proteins were visualized with colloidal Coomassie brilliant blue or silver staining.
2.1.3. Two-dimensional Western blot analysis
The 2-DE-separated proteins were electroblotted onto nitrocellulose membranes (HyBond ECL; GE
Healthcare). The 2-D blots were stained with SYPRO Ruby protein blot stain (Bio-Rad) as reported [2],
and then digitalized using an epi illuminated laser-scanning instrument (Molecular Imager FX; Bio-
Rad) and the Quantity-One software (Bio-Rad). After rinsing, serum samples from candidemia and
control patients (1:100 dilution) were individually assessed by Western blotting for IgG antibodies to
proteins onto the 2-D blots, and tested in two independent assays as described [2,5]. The recognition
intensity of each discrete antigenic protein species was estimated as the integrated optical density of
its spot area after background subtraction and normalization to its SYPRO-Ruby-stained counterpart
(loading control) using the ImageMaster 2D Platinum software v.5.0 (GE Healthcare), and expressed
as arbitrary units (AU). Protein spots immunodetected with serum samples from two or more training
patients were then identiﬁed using our reference 2-D map of C. albicans immunogenic proteins [6,7],
which is also available on our COMPLUYEAST-2DPAGE database [8,9]. Proteins from this map were
characterized previously by PMF [6,10,11] and MS/MS [6,12]. As a ﬁrst step towards the analysis of the
speciation of the C. albicans immunome, the immunoreactive protein spots of C. albicans Tdh3 were
selected for initial chemical characterization analyses, which were carried out as detailed below.
2.2. MS analysis for chemical characterization of C. albicans Tdh3
2.2.1. In-gel digestion
The distinct protein spots of C. albicans Tdh3 that were immunorecognized by serum specimens
from candidemia patients were manually excised with a scalpel from a colloidal Coomassie-stained
preparative 2-DE gel. The excised gel pieces were then in-gel destained, reduced, alkylated, and
digested with trypsin as reported [7,13].
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The resulting tryptic peptides were analyzed using a MALDI-TOF/TOF mass spectrometer (4800
Plus Proteomics Analyzer; AB Sciex, Framingham, MA) and the 4000 Series Explorer software v.3.7.0
(AB Sciex). MS spectra (peptide mass ﬁngerprints) were acquired in reﬂector positive-ion mode using
1000 laser shots per spectrum, and internally calibrated using trypsin autodigestion products (m/z
values, 805.46, 906.50, 1153.57, 1433.72 and 2163.05 [14]). MS/MS spectra were acquired by selecting
some precursor ions from peptide mass ﬁngerprints (see below), and averaging 2000 laser shots per
spectrum. The selected precursor ions were fragmented by collision-induced dissociation using an
isolation width of 710 Da, collision energy of 1 kV, and ambient air as the collision gas. MS and MS/
MS peak ﬁltering was carried out through the Global Protein Server (GPS) Explorer software v.3.6 (AB
Sciex) using the following parameters: signal-to-noise threshold, 20 for MS mode and 10 for MS/MS
mode; resolution, higher than 10,000 for MS mode and 6000 for MS/MS mode; mass range, 850–
4000 Da for MS mode and 10 Da up to precursor ion mass for MS/MS mode; and ion exclusion,
peptide ions from trypsin autodigestion and matrix.2.2.3. De novo peptide sequencing
PMF data were examined with the FindMod web-based tool (http://web.expasy.org/ﬁndmod/) to
search for and select potential post-translationally modiﬁed peptides. The search parameters were as
follows: enzyme, trypsin; modiﬁcations, S-carbamidomethylation of Cys and oxidation of Met; ion
mode, [MþH]þ; mass values, monoisotopic; peptide mass tolerance, 710 ppm; and number of
missed cleavage sites, up to 1. The selected precursor ions were analyzed by MALDI-TOF/TOF MS as
described above. After MS/MS peak ﬁltering, their amino acid sequences were deduced de novo both
by manual interpretation and with the DeNovo Explorer software (AB Sciex) on the basis of assign-
ment of the N-terminal b-ion and C-terminal y-ion series. Computer-assisted interpretation was
performed using the following parameters: enzyme, trypsin; ﬁxed modiﬁcations, S-carbamido-
methylation of Cys; variable modiﬁcations, PTMs predicted by the FindMod tool and manually
deduced de novo; and fragment mass tolerance: 70.3 Da. The UniMod database (http://www.
unimod.org) and Delta Mass database (http://www.abrf.org) were used to search for potential natural
or artiﬁcial PTMs associated with a given average mass change between the unmodiﬁed and modiﬁed
precursor ions. The criteria applied to generate conﬁdent peptide sequences de novo and accept the
presence and site of protein PTMs were the detection of (i) distinctive mass losses or modiﬁcation-
speciﬁc neutral moieties (neutral loss), (ii) the immonium ions of the chemically modiﬁed amino acid
residues, (iii) the product ions corresponding to the chemically modiﬁed amino acid residues and the
N- and C-terminal residues adjacent to the modiﬁed residues, with veriﬁcation that the former had
the PTM and the latter lacked it, or (iv) the immonium ions of the chemically modiﬁed amino acid
residues as well as the product ions corresponding to the N- and C-terminal residues adjacent to the
modiﬁed residues, with conﬁrmation that the latter lacked the PTM.2.2.4. Database search
Database searches of PMF and MS/MS data for protein identiﬁcation were carried out through the
GPS Explorer software on a local license of the Mascot Server software v.2.3 (Matrix Science, Boston,
MA) using a non-redundant protein database (NCBInr; http://www.ncbi.nlm.nih.gov) without tax-
onomy restriction and the Candida Genome Database (CGD; http://www.candidagenome.org) under
the following parameters: enzyme, trypsin; ﬁxed modiﬁcations, S-carbamidomethylation of Cys;
variable modiﬁcations, oxidation of Met or de novo deduced PTMs (for chemically modiﬁed peptides);
mass values, monoisotopic; molecular mass and pI; unrestricted; peptide charge, þ1; peptide mass
tolerance, 750 ppm; fragment mass tolerance: 70.3 Da; and number of missed cleavage sites, up to
1. In all identiﬁcations, protein and ions scores were greater than those reported by the Mascot Server
software as signiﬁcant (po0.05) for PMF and MS/MS data, respectively.
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